返回 
加入收藏
卡瑞利珠单抗联合阿帕替尼与其联合化疗方案一线治疗晚期胃癌的临床效果对比
x
请在关注微信后，向客服人员索取文件
| 篇名： | 卡瑞利珠单抗联合阿帕替尼与其联合化疗方案一线治疗晚期胃癌的临床效果对比 |
| TITLE： | Clinical efficacy of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy regimens as first-line treatment for advanced gastric cancer |
| 摘要： | 目的 对比卡瑞利珠单抗联合阿帕替尼与卡瑞利珠单抗联合化疗方案一线治疗晚期胃癌的临床疗效及安全性。方法采用前瞻性随机对照研究设计，将滁州市第一人民医院2022年3月至2024年12月收治的99例晚期胃癌患者按照随机数字表法分组，其中48例采用卡瑞利珠单抗联合化疗方案治疗（对照组），51例采用卡瑞利珠单抗联合阿帕替尼治疗（观察组）。比较两组患者治疗后的临床疗效，治疗前后的血清肿瘤标志物[癌胚抗原（CEA）、糖类抗原（CA）724、CA199和CA242]和免疫功能指标（CD3+、CD4+、CD8+及CD4+/CD8+）水平，以及治疗期间药物不良反应（ADR）发生情况。结果观察组和对照组分别有2、3例患者脱落。观察组患者的疾病控制率与客观缓解率分别为95.92%、85.71%，分别显著高于对照组的80.00%、55.56%（P＜0.05）。观察组患者的中位无进展生存期为9.61个月，显著长于对照组的6.72个月（P＝0.011）。治疗前，两组患者的各项血清肿瘤标志物和免疫功能指标水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者的CEA、CA724、CA199、CA242水平均显著低于治疗前，CD3+、CD4+水平及CD4+/CD8+值均显著高于治疗前，且观察组均显著优于对照组（P＜0.05）。两组患者ADR总发生率和严重ADR发生率比较，差异均无统计学意义（P＞0.05）。结论卡瑞利珠单抗联合阿帕替尼作为晚期胃癌一线治疗方案在临床疗效和患者免疫功能改善方面较卡瑞利珠单抗联合化疗方案具有一定优势，且总体安全性可接受。 |
| ABSTRACT： | OBJECTIVE To compare the clinical efficacy and safety of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy as first-line treatment for advanced gastric cancer. METHODS A prospective randomized controlled trial was conducted， enrolling 99 patients with advanced gastric cancer admitted to the Chuzhou First People’s Hospital from March 2022 to December 2024. Patients were randomly assigned using a random number table： 48 received camrelizumab plus chemotherapy （control group）， and 51 received camrelizumab plus apatinib （observation group）. Clinical efficacy， serum tumor marker[carcinoembryonic antigen（CEA），carbohydrate antigen（CA）724，CA199，CA242]levels， immune function indicators（CD3+，CD4+，CD8+，CD4+/CD8+） levels before and after treatment， and adverse drug reaction （ADR） during treatment were compared between the 2 groups. RESULTS A total of 2 patients in the observation group and 3 in the control group were lost to follow-up. The disease control rate and objective response rate in the observation group were 95.92% and 85.71%， respectively， both significantly higher than 80.00% and 55.56% in the control group （P＜0.05）. The median progression-free survival was 9.61 months in the observation group， significantly longer than 6.72 months in the control group （P＝0.011）. Before treatment， there was no statistically significant difference in the levels of serum tumor markers and immune function indicators between the 2 groups （P＞0.05）. After treatment， the levels of CEA， CA724， CA199 and CA242 in 2 groups were significantly lower than before treatment， while the levels of CD3⁺， CD4⁺ and CD4 ⁺/CD8 ⁺ were significantly higher than before treatment， with greater improvements in the observation group （all P＜0.05）. The overall incidences of ADR and severe ADR showed no statistically significant difference between the 2 groups （P＞0.05）. CONCLUSIONS Camrelizumab combined with apatinib as first-line therapy for advanced gastric cancer may offer advantages over camrelizumab plus chemotherapy in terms of clinical efficacy and immune function improvement of patients， with an acceptable safety profile. |
| 期刊： | 2025年第36卷第18期 |
| 作者： | 琚然；缪琦；杨军；王永贵；董祥宁 |
| AUTHORS： | JU Ran，MIAO Qi，YANG Jun，WANG Yonggui，DONG Xiangning |
| 关键字： | 卡瑞利珠单抗；阿帕替尼；晚期胃癌；临床疗效；免疫功能；化疗相关毒性 |
| KEYWORDS： | camrelizumab； apatinib； advanced gastric cancer； clinical efficacy； immune function； chemotherapy-related |
| 阅读数： | 9 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
